bb 2121

Drug Profile

bb 2121

Alternative Names: Anti-BCMA CAR T cells - bluebird bio/Celgene; BB-2121; bb2121

Latest Information Update: 15 Jun 2017

Price : $50

At a glance

  • Originator bluebird bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action B-cell maturation antigen modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 05 Jun 2017 Adverse events data from a phase I trial in Multiple myeloma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 09 Jan 2017 Celgene plans a phase II trial for Multiple myeloma in
  • 30 Nov 2016 Interim efficacy and adverse events data from the phase I CRB-401 trial in Multiple myeloma (Second-line therapy or greater) released by bluebird bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top